Strahlentherapie und Onkologie

, Volume 174, Issue 5, pp 288–289

Wirtschaftlichkeitsanalyse der adjuvanten Interferon-alpha-2b-Therapie bei Hochrisiko-Melanompatienten aufgrund von Ergebnissen der Studie ECOG 1684

  • Wolfgang Hoffmann
Literatur Kommentiert
  • 20 Downloads

Literatur

  1. 1.
    Gold MR, Siegel JE, Russel LE et al. eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University, 1996.Google Scholar
  2. 2.
    Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Hillner BE et al. Economic analysis of adjuvant interferon-alpha 2a in high risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;6:2351–8.Google Scholar
  4. 4.
    Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon-a-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.PubMedGoogle Scholar
  5. 5.
    Kochanek KD, Hudson BL. Advance report of final mortaility statistics, 1992. In: Monthly vital statistics report, Vol. 43. Hyattsville, MD: National Center for Health Statistics, 1995.Google Scholar

Copyright information

© Urban & Vogel 1998

Authors and Affiliations

  • Wolfgang Hoffmann
    • 1
  1. 1.Tübingen

Personalised recommendations